Abstract
Introduction
Studies investigating the aripiprazole augmentation treatment of serotonin reuptake inhibitor (SRI)-resistant obsessive-compulsive disorder (OCD) are insufficient. The aim of the present pilot study was to investigate the efficacy and tolerability of flexible doses of aripiprazole as an augmenting agent in SRI-resistant OCD patients.
Methods
OCD patients who met the criteria of this study were followed up with flexible doses of aripiprazole augmentation over a 10-week period. Effectiveness of treatment was evaluated via the Yale-Brown Obsessive Compulsive Scale (Y-BOCS) and Clinical Global Impressions-Severity of Illness (CGI-S) and -Improvement (CGI-I) scales. At the end of the 10-week follow-up period, patients who showed an improvement of ≥30% for the Y-BOCS total score from baseline were considered responders.
Results
Thirty patients met the study inclusion criteria; three patients did not agree to participate, and four patients dropped out of the study. The differences between baseline and scores at 10 weeks for the parameters studied were as follows: Y-BOCS scores: 32.0±6.3–24.0±8.1 (Z=4.2, P<0.05); Y-BOCS compulsion subscore: 15.0±4.2–11.5±4.3 (Z=4.01, P<0.05); Y-BOCS obsession subscore: 17.0±2.6–12.4±4.0 (Z=4.1, P<0.05); and CGI-S scores: 4.8±0.8–3.1±1.2 (Z=3.9, P<0.05). Patients showed a significant improvement over the 10-week study period; however, only seven of 23 patients (30.4%) who completed the study met the criteria determined for treatment response.
Conclusion
Despite the limited number of cases and open-label design of this study, results support the notion that adding aripiprazole to SRIs could be a valid strategy for treatmentresistant OCD patients.
Similar content being viewed by others
References
Maina G, Pessina E, Albert U, Bogetto F. 8-week, single-blind, randomized trial comparing risperidone versus olanzapine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder. Eur Neuropsychopharmacol. 2008;18:364–372.
Decloedt EH, Stein DJ. Current trends in drug treatment of obsessive-compulsive disorder. Neuropsychiatr Dis Treat. 2010;6:233–242.
Kellner M. Drug treatment of obsessive-compulsive disorder. Dialogues Clin Neurosci. 2010;12:187–197.
Marazziti D, Pfanner C, Dell’Osso B, et al. Augmentation strategy with olanzapine in resistant obsessive compulsive disorder: an Italian long-term open-label study. J Psychopharmacol. 2005;19:392–394.
Komossa K, Depping AM, Meyer M, Kissling W, Leucht S. Second-generation antipsychotics for obsessive compulsive disorder. Cochrane Database Syst Rev. 2010;12:CD008141.
Choi YJ. Efficacy of treatments for patients with obsessive-compulsive disorder: a systematic review. J Am Acad Nurse Pract. 2009;21:207–213.
Soygur H. Pharmacokinetic and pharmacodynamic characteristics of aripiprazole. Klinik Psikofarmakoloji Bulteni. 2008;18:1–6.
DeLeon A, Patel NC, Crismon ML. Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clin Ther. 2004;26:649–666.
Monkul ES, Akdede BB. Aripiprazole: a new atypical antipsyhotic [sic] drug. Klinik Psikofarmakoloji Bulteni. 2005;15:198–203.
Pessina E, Albert U, Bogetto F, Maina G. Aripiprazole augmentation of serotonin reuptake inhibitors in treatment-resistant obsessivecompulsive disorder: a 12-week open-label preliminary study. Int Clin Psychopharmacol. 2009;24:265–269.
Connor KM, Payne VM, Gadde KM, Zhang W, Davidson JR. The use of aripiprazole in obsessivecompulsive disorder: preliminary observations in 8 patients. J Clin Psychiatry. 2005;66:49–51.
Sarkar R, Klein J, Kruger S. Aripiprazole augmentation in treatment-refractory obsessivecompulsive disorder. Psychopharmacology (Berl). 2008;197:687–688.
da Rocha FF, Correa H. Successful augmentation with aripiprazole in clomipraminerefractory obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:1550–1551.
Masi G, Pfanner C, Millepiedi S, Berloffa S. Aripiprazole augmentation in 39 adolescents with medication-resistant obsessive-compulsive disorder. J Clin Psychopharmacol. 2010;30:688–693.
Tek C, Ulug B, Rezaki BG, et al. Yale-Brown Obsessive Compulsive Scale and US National Institute of Mental Health Global Obsessive Compulsive Scale in Turkish: reliability and validity. Acta Psychiatr Scand. 1995;91:410–413.
Akdemir A, Turkcapar MH, Orsel SD, Demirergi N, Dag I, Ozbay MH. Reliability and validity of the Turkish version of the Hamilton Depression Rating Scale. Compr Psychiatry. 2001;42:161–165.
Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl. 1987;334:1–100.
Koo MS, Kim EJ, Roh D, Kim CH. Role of dopamine in the pathophysiology and treatment of obsessivecompulsive disorder. Expert Rev Neurother. 2010;10:275–290.
Perani D, Garibotto V, Gorini A, et al. In vivo PET study of 5HT(2A) serotonin and D(2) dopamine dysfunction in drug-naive obsessive-compulsive disorder. Neuroimage. 2008;42:306–314.
Denys D, Zohar J, Westenberg HG. The role of dopamine in obsessive-compulsive disorder: preclinical and clinical evidence. J Clin Psychiatry. 2004;65(suppl. 14):11–17.
Pae CU. Comments on “Aripiprazole in major depression and mania: meta-analyses of randomized placebo-controlled trials”. Gen Hosp Psychiatry. 2010;32:448; author reply 449.
Arias Horcajadas F, Soto JA, Garcia-Cantalapiedra MJ, Rodriguez Calvin JL, Morales J, Salgado M. Effectiveness and tolerability of addition of risperidone in obsessive-compulsive disorder with poor response to serotonin reuptake inhibitors. Actas Esp Psiquiatr. 2006;34:147–152.
Bystritsky A, Ackerman DL, Rosen RM, et al. Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial. J Clin Psychiatry. 2004;65:565–568.
Nelson JC, Thase ME, Trivedi MH, et al. Safety and tolerability of adjunctive aripiprazole in major depressive disorder: a pooled post hoc snalysis (studies CN138-139 and CN138-163). Prim Care Companion J Clin Psychiatry. 2009;11:344–352.
Padala PR, Sadiq HJ, Padala KP. Urinary obstruction with citalopram and aripiprazole combination in an elderly patient. J Clin Psychopharmacol. 2006;26:667–668.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ak, M., Bulut, S.D., Bozkurt, A. et al. Aripiprazole augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a 10-week open-label study. Adv Therapy 28, 341–348 (2011). https://doi.org/10.1007/s12325-011-0011-7
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12325-011-0011-7